Relevant bibliographies by topics / Plasmid production

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Plasmid production'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Plasmid production.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Plasmid production"

1

Trivedi, Ram Narayan, Parvez Akhtar, Jonathan Meade, Patrick Bartlow, Mohammad M. Ataai, Saleem A. Khan, and Michael M. Domach. "High-Level Production of Plasmid DNA by Escherichia coli DH5α ΩsacBby IntroducingincMutations." Applied and Environmental Microbiology 80, no. 23 (September 12, 2014): 7154–60. http://dx.doi.org/10.1128/aem.02445-14.

Full text
Abstract:
ABSTRACTFor small-copy-number pUC-type plasmids, theinc1andinc2mutations, which deregulate replication, were previously found to increase the plasmid copy number 6- to 7-fold. Because plasmids can exert a growth burden, it was not clear if further amplification of copy number would occur due toincmutations when the starting point for plasmid copy number was orders of magnitude higher. To investigate further the effects of theincmutations and the possible limits of plasmid synthesis, the parent plasmid pNTC8485 was used as a starting point. It lacks an antibiotic resistance gene and has a copy number of ∼1,200 per chromosome. During early stationary-phase growth in LB broth at 37°C,inc2mutants of pNTC8485 exhibited a copy number of ∼7,000 per chromosome. In minimal medium at late log growth, the copy number was found to be significantly increased, to approximately 15,000. In an attempt to further increase the plasmid titer (plasmid mass/culture volume), enzymatic hydrolysis of the selection agent, sucrose, at late log growth extended growth and tripled the total plasmid amount such that an approximately 80-fold gain in total plasmid was obtained compared to the value for typical pUC-type vectors. Finally, when grown in minimal medium, no detectable impact on the exponential growth rate or the fidelity of genomic or plasmid DNA replication was found in cells with deregulated plasmid replication. The use ofincmutations and the sucrose degradation method presents a simplified way for attaining high titers of plasmid DNA for various applications.
APA, Harvard, Vancouver, ISO, and other styles
2

Kojic, Milan, Ivana Strahinic, Djordje Fira, Branko Jovcic, and Ljubisa Topisirovic. "Plasmid content and bacteriocin production by five strains ofLactococcus lactisisolated from semi-hard homemade cheese." Canadian Journal of Microbiology 52, no. 11 (November 1, 2006): 1110–20. http://dx.doi.org/10.1139/w06-072.

Full text
Abstract:
In this study, the plasmid content and bacteriocin production of natural isolates of lactococci were investigated. Five bacteriocin producing lactococcal strains (Lactococcus lactis subsp. lactis BGMN1-2, BGMN1-3, BGMN1-5, BGMN1-6, and BGMN2-7) were isolated as nonstarter microflora of semi-hard homemade cheese and characterized. All isolates contained a number of plasmids. It was shown that lcnB structural genes for bacteriocin lactococcin B were located on large plasmids in all isolates. In the strains BGMN1-3 and BGMN1-5 proteinase prtP genes collocated with lcnB. Furthermore, these strains produced two additional bacteriocins (LsbA and LsbB) with genes responsible for their production and immunity located on the small rolling circle-replicating plasmid pMN5. Using deletion experiments of pMN5, minimal replicon of the plasmid and involvement of a bacteriocin locus in plasmid maintenance were identified. In addition, plasmid curing experiments showed that genes for catabolism or transport of 10 carbohydrates in the strain BGMN1-5 were plasmid located.Key words: lactococci, natural isolates, bacteriocin, plasmid curing.
APA, Harvard, Vancouver, ISO, and other styles
3

Münch, Karin M., Johannes Müller, Sarah Wienecke, Simone Bergmann, Steffi Heyber, Rebekka Biedendieck, Richard Münch, and Dieter Jahn. "Polar Fixation of Plasmids during Recombinant Protein Production in Bacillus megaterium Results in Population Heterogeneity." Applied and Environmental Microbiology 81, no. 17 (June 26, 2015): 5976–86. http://dx.doi.org/10.1128/aem.00807-15.

Full text
Abstract:
ABSTRACTDuring the past 2 decades,Bacillus megateriumhas been systematically developed for the gram-per-liter scale production of recombinant proteins. The plasmid-based expression systems employed use a xylose-controlled promoter. Protein production analyses at the single-cell level using green fluorescent protein as a model product revealed cell culture heterogeneity characterized by a significant proportion of less productive bacteria. Due to the enormous size ofB. megaterium, such bistable behavior seen in subpopulations was readily analyzed by time lapse microscopy and flow cytometry. Cell culture heterogeneity was not caused simply by plasmid loss: instead, an asymmetric distribution of plasmids during cell division was detected during the exponential-growth phase. Multicopy plasmids are generally randomly distributed between daughter cells. However,in vivo andin vitroexperiments demonstrated that under conditions of strong protein production, plasmids are retained at one of the cell poles. Furthermore, it was found that cells with accumulated plasmids and high protein production ceased cell division. As a consequence, the overall protein production of the culture was achieved mainly by the subpopulation with a sufficient plasmid copy number. Based on our experimental data, we propose a model whereby the distribution of multicopy plasmids is controlled by polar fixation under protein production conditions. Thereby, cell lines with fluctuating plasmid abundance arise, which results in population heterogeneity. Our results provide initial insights into the mechanism of cellular heterogeneity during plasmid-based recombinant protein production in aBacillusspecies.
APA, Harvard, Vancouver, ISO, and other styles
4

Fong, Ryan, Zhihao Hu, C. Richard Hutchinson, Jianqiang Huang, Stanley Cohen, and Camilla Kao. "Characterization of a Large, Stable, High-Copy-Number Streptomyces Plasmid That Requires Stability and Transfer Functions for Heterologous Polyketide Overproduction." Applied and Environmental Microbiology 73, no. 4 (December 1, 2006): 1296–307. http://dx.doi.org/10.1128/aem.01888-06.

Full text
Abstract:
ABSTRACT A major limitation to improving small-molecule pharmaceutical production in streptomycetes is the inability of high-copy-number plasmids to tolerate large biosynthetic gene cluster inserts. A recent finding has overcome this barrier. In 2003, Hu et al. discovered a stable, high-copy-number, 81-kb plasmid that significantly elevated production of the polyketide precursor to the antibiotic erythromycin in a heterologous Streptomyces host (J. Ind. Microbiol. Biotechnol. 30:516-522, 2003). Here, we have identified mechanisms by which this SCP2*-derived plasmid achieves increased levels of metabolite production and examined how the 45-bp deletion mutation in the plasmid replication origin increased plasmid copy number. A plasmid intramycelial transfer gene, spd, and a partition gene, parAB, enhance metabolite production by increasing the stable inheritance of large plasmids containing biosynthetic genes. Additionally, high product titers required both activator (actII-ORF4) and biosynthetic genes (eryA) at high copy numbers. DNA gel shift experiments revealed that the 45-bp deletion abolished replication protein (RepI) binding to a plasmid site which, in part, supports an iteron model for plasmid replication and copy number control. Using the new information, we constructed a large high-copy-number plasmid capable of overproducing the polyketide 6-deoxyerythronolide B. However, this plasmid was unstable over multiple culture generations, suggesting that other SCP2* genes may be required for long-term, stable plasmid inheritance.
APA, Harvard, Vancouver, ISO, and other styles
5

Fridjonsson, Olafur, and Ralf Mattes. "Production of Recombinant α-Galactosidases inThermus thermophilus." Applied and Environmental Microbiology 67, no. 9 (September 1, 2001): 4192–98. http://dx.doi.org/10.1128/aem.67.9.4192-4198.2001.

Full text
Abstract:
ABSTRACT A Thermus thermophilus selector strain for production of thermostable and thermoactive α-galactosidase was constructed. For this purpose, the native α-galactosidase gene (agaT) ofT. thermophilus TH125 was inactivated to prevent background activity. In our first attempt, insertional mutagenesis ofagaT by using a cassette carrying a kanamycin resistance gene led to bacterial inability to utilize melibiose (α-galactoside) and galactose as sole carbohydrate sources due to a polar effect of the insertional inactivation. A Gal+ phenotype was assumed to be essential for growth on melibiose. In a Gal−background, accumulation of galactose or its metabolite derivatives produced from melibiose hydrolysis could interfere with the growth of the host strain harboring recombinant α-galactosidase. Moreover, the AgaT− strain had to be Kms for establishment of the plasmids containing α-galactosidase genes and the kanamycin resistance marker. Therefore, a suitable selector strain (AgaT− Gal+ Kms) was generated by applying integration mutagenesis in combination with phenotypic selection. To produce heterologous α-galactosidase in T. thermophilus, the isogenes agaA and agaBof Bacillus stearothermophilus KVE36 were cloned into anEscherichia coli-Thermus shuttle vector. The region containing the E. coli plasmid sequence (pUC-derived vector) was deleted before transformation of T. thermophilus with the recombinant plasmids. As a result, transformation efficiency and plasmid stability were improved. However, growth on minimal agar medium containing melibiose was achieved only following random selection of the clones carrying a plasmid-based mutation that had promoted a higher copy number and greater stability of the plasmid.
APA, Harvard, Vancouver, ISO, and other styles
6

Chakrabarty, P. K., Sheo Raj, M. K. Meshram, A. Mahadevan, and D. W. Gabriel. "Plasmid-borne determinants of pigmentation, exopolysaccharide production, and virulence in Xanthomonas campestris pv. malvacearum." Canadian Journal of Microbiology 41, no. 8 (August 1, 1995): 740–45. http://dx.doi.org/10.1139/m95-101.

Full text
Abstract:
Three plasmids of 55.0, 31.2, and 7.4 kb, designated as pXCM18-I, pXCM18-II, and pXCM18-III, respectively, were identified and isolated from strain HR13B/2 of Xanthomonas campestris pv. malvacearum. The bacterium was cured of all three plasmids in high frequency (3.1%) with heat (42 °C). The cured strains were nonmucoid and light yellow and were greatly impaired in exopolysaccharide production and virulence. Transformation of a cured strain using a mixture of purified plasmid DNA from HR13B/2 resulted in colonies carrying all six possible combinations of the three plasmids. Of the transformants, two morphologically distinct colony types were observed. The first type of transformants were mucoid and deep yellow, not distinguished from wild-type colonies in morphology, and fully complemented for exopolysaccharide production. These transformants invariably carried pXCM18-II. The second type of transformants were not distinguished from the untransformed strain in morphology but were found to be transformed after screening for plasmid content. These transformants carried either pXCM18-I, pXCM18-III, or both, but never pXCM18-II. In pathogenicity tests, each of the three plasmids restored virulence significantly, and additively, with plasmid pXCM18-I playing a predominant role.Key words: Xanthomonas campestris pv. malvacearum, cotton, plasmid, pigmentation, exopolysaccharide, virulence.
APA, Harvard, Vancouver, ISO, and other styles
7

McMillan, Elizabeth A., Jamie L. Wasilenko, Kaitlin A. Tagg, Jessica C. Chen, Mustafa Simmons, Sushim K. Gupta, Glenn E. Tillman, Jason Folster, Charlene R. Jackson, and Jonathan G. Frye. "Carriage and Gene Content Variability of the pESI-Like Plasmid Associated with Salmonella Infantis Recently Established in United States Poultry Production." Genes 11, no. 12 (December 18, 2020): 1516. http://dx.doi.org/10.3390/genes11121516.

Full text
Abstract:
Salmonella Infantis carrying extended spectrum β-lactamase blaCTX-M-65 on a pESI-like megaplasmid has recently emerged in United States poultry. In order to determine the carriage rate and gene content variability of this plasmid in U.S. Salmonella Infantis, whole genome sequences of Salmonella isolates from humans and animals in the U.S. and internationally containing the pESI-like plasmid were analyzed. The U.S. Department of Agriculture Food Safety and Inspection Service (FSIS) identified 654 product sampling isolates containing pESI-like plasmids through hazard analysis and critical control point (HACCP) verification testing in 2017 and 2018. The Centers for Disease Control and Prevention identified 55 isolates with pESI-like plasmids in 2016–2018 through the National Antimicrobial Resistance Monitoring System. Approximately 49% of pESI-like plasmids from FSIS verification isolates and 71% from CDC NARMS contained blaCTX-M-65. Pan-plasmid genome analysis was also performed. All plasmids contained traN and more than 95% contained 172 other conserved genes; 61% contained blaCTX-M-65. In a hierarchical clustering analysis, some plasmids from U.S. animal sources clustered together and some plasmids from South America clustered together, possibly indicating multiple plasmid lineages. However, most plasmids contained similar genes regardless of origin. Carriage of the pESI-like plasmid in U.S. appears to be limited to Salmonella Infantis and carriage rates increased from 2017 to 2018.
APA, Harvard, Vancouver, ISO, and other styles
8

Ishibashi, Y. "Genetic Studies into Musty Odor Production by Actinomycetes." Water Science and Technology 25, no. 2 (January 1, 1992): 171–76. http://dx.doi.org/10.2166/wst.1992.0049.

Full text
Abstract:
Musty taste and odor is a serious problem for drinking water. Much data regarding its occurrence are being accumulated. However, we may be able to solve this problem by inquiring into the nature of secondary metabolism through the mevalonic acid pathway in actinomycetes and/or cyanobacteria that yield musty smelling compounds. Therefore, genetic analysis is applied to look for new solutions. By investigating Streptomyces sp. with the protocol to recover plasmid DNA, it was difficult to get the infinitesimally small covalently closed circular (ccc) plasmid. On the other hand, Streptomyces strains which have been cured, which implicates plasmids, lost phenotypic characters such as musty odor production with aerial mycelium and pigment formation. DNA in Streptomyces are unstable and often cause amplification and deletion. The existence of giant linear plasmids was detected in musty smelling strains using pulsed – field gel electrophoresis.
APA, Harvard, Vancouver, ISO, and other styles
9

Hausjell, Johanna, Regina Kutscha, Jeannine D. Gesson, Daniela Reinisch, and Oliver Spadiut. "The Effects of Lactose Induction on a Plasmid-Free E. coli T7 Expression System." Bioengineering 7, no. 1 (January 6, 2020): 8. http://dx.doi.org/10.3390/bioengineering7010008.

Full text
Abstract:
Recombinant production of pharmaceutical proteins like antigen binding fragments (Fabs) in the commonly-used production host Escherichia coli presents several challenges. The predominantly-used plasmid-based expression systems exhibit the drawback of either excessive plasmid amplification or plasmid loss over prolonged cultivations. To improve production, efforts are made to establish plasmid-free expression, ensuring more stable process conditions. Another strategy to stabilize production processes is lactose induction, leading to increased soluble product formation and cell fitness, as shown in several studies performed with plasmid-based expression systems. Within this study we wanted to investigate lactose induction for a strain with a genome-integrated gene of interest for the first time. We found unusually high specific lactose uptake rates, which we could attribute to the low levels of lac-repressor protein that is usually encoded not only on the genome but additionally on pET plasmids. We further show that these unusually high lactose uptake rates are toxic to the cells, leading to increased cell leakiness and lysis. Finally, we demonstrate that in contrast to plasmid-based T7 expression systems, IPTG induction is beneficial for genome-integrated T7 expression systems concerning cell fitness and productivity.
APA, Harvard, Vancouver, ISO, and other styles
10

Carnes,, Aaron E. "High-Yield Plasmid DNA Production." Genetic Engineering & Biotechnology News 32, no. 8 (April 15, 2012): 42–43. http://dx.doi.org/10.1089/gen.32.8.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Plasmid production"

1

O'Mahony, Kevin. "Large scale plasmid production /." [S.l.] : [s.n.], 2005. http://library.epfl.ch/theses/?nr=3320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yap, Wee Ching Melvyn. "Analysis of retroviral production in murine leukaemia virus." Thesis, University of Oxford, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.325497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bower, Diana M. (Diana Morgan). "Development of new tools for the production of plasmid DNA biopharmaceuticals." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/76475.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references (p. 96-104).
DNA vaccines and gene therapies that use plasmid DNA (pDNA) as a vector have gained attention in recent years for their good safety profile, ease of manufacturing, and potential to treat a host of diseases. With this interest comes increased demand for high-yield manufacturing processes. Overall, this thesis aims to develop new, innovative tools for the production of plasmid DNA biopharmaceuticals. As one part of this thesis, we designed a 1-mL fed-batch microbioreactor with online monitoring and control of dissolved oxygen, pH, and temperature, as well as continuous monitoring of cell density. We used the microbioreactors to scale down temperature-induced production of a pUC-based DNA vaccine vector, pVAX1-GFP. Scaled-down processes can facilitate high-thoughtput, low-cost bioprocess development. We found that the microbioreactors accurately reproduced the behavior of a bench-scale bioreactor as long as key process parameters, such as dissolved oxygen, were held constant across scales. The monitoring capabilities of the microbioreactors also provided enhanced process insight and helped identify conditions that favored plasmid amplification. A second aspect of this thesis involved construction and characterization of a new DNA vaccine vector based on a runaway replication mutant of the R1 replicon. Runaway replication plasmids typically show increased amplification after a temperature upshift. However, we found that our new vector, pDMB02-GFP, gave higher yields during constant temperature culture at 30"C, reaching a maximum of 19 mg pDNA/g DCW in shake flasks. We gained mechanistic insight into this behavior by measuring RNA and protein expression levels of RepA, a plasmid-encoded protein required for initiation of replication at the R1 origin. Through these studies we found that RepA levels may limit plasmid amplification at 42*C, and relieved this limitation by increasing RepA translation efficiency via a start codon mutation. We also scaled up production of pDMB02-GFP at 300C from 50-mL shake flasks to 2-L bioreactors. Initial scale up efforts resulted in increased growth rate compared to the shake flasks, accompanied by very low plasmid yields. Decreasing the growth rate by limiting dissolved oxygen increased plasmid specific yield and emerged as a viable strategy for maintaining productivity during scale up.
by Diana M. Bower.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
4

Hales, Barbara A. "Plasmid determined fimbrial production responsible for bacterial colonization of the urinary tract." Thesis, University of Edinburgh, 1985. http://hdl.handle.net/1842/23962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cheng, Chinyuan. "Engineering strategies to optimize plasmid stability and protein production in recombinant Saccharomyces cerevisiae fermentation /." The Ohio State University, 1992. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487779914824623.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chamsart, Saedthawat. "A cell lysis reactor for the production of plasmid DNA from recombinant E.coli for gene therapy." Thesis, University of Birmingham, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.366017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pensri, Charoensit. "Development of inhibition methods for pro-inflammatory cytokine production induced by cationic carrier/plasmid DNA complex." 京都大学 (Kyoto University), 2009. http://hdl.handle.net/2433/126605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Robinson, Susan Clare. "Enhanced production of a recombinant, thermostable alpha-amylase in Streptomyces lividans : effects of plasmid construction and culture conditions." Thesis, University College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.393582.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

García, Mark Megan Olga. "Production and validation of anti-HCV antibodies for viral neutralization." Thesis, KTH, Skolan för kemi, bioteknologi och hälsa (CBH), 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-278578.

Full text
Abstract:
Hepatitis-C Virus (HCV) remains the leading cause of liver transplant in the US and the UK, and the World Health Organization (WHO) estimates that 71 million people are infected worldwide. A vaccine would drastically impact the healthcare-associated burdens that HCV causes globally. The objective of this master’s thesis project is to produce human antibody (IgG) against HCV. This project will focus on the monoclonal antibodies (mAbs) HEPC3, AR3C, HEPC74, and HCV1. These four antibodies have been isolated from patients who have successfully cleared the infection, and their sequences and structures are available in the public domain. These four antibodies have also shown to bind to E2, a glycoprotein on the surface HCV that is crucial for viral binding and entry. This interaction of the mABs with E2 has been implicated in viral neutralization, making them promising choices for this study. Overall, 3 out of 4 mAbs were successfully cloned and produced. The unsuccessful antibody, HEPC74, was discovered to have failed due to an error in the plasmid sequence. Just as the western blot to confirm secretion was ready to be run, the laboratory closed due the Covid-19 outbreak. Therefore, the data can officially declare a ¾ mAb production success, however it is safe to assume that the alternative clone for HEPC74 was also a success due to a perfect sequence match. Since the primary objective of this project was to successfully clone and produce these four antibodies, then this study is considered an overall success. Lastly, this study examined how the same protocol  could be applied the SARS-CoV-2 outbreak, by the cloning and production of anti-RBD IgG and testing them for viral neutralization.
Hepatit-C (HCV) är fortsatt den enskilt största orsaken till levertransplantationer med uppskattningsvis 71 miljoner infekterade globalt sett, enligt världshälsoorganisationen (WHO).Ett vaccin mot HCV skulle drastiskt minska trycket på global hälso- och sjukvård. Syftet med detta projekt är att producera antikroppar (igG) mot HCV. Projektet fokuserar på HEPC3, AR3C, HEPC74 och HCV1 som är monoklonala antikroppar (mAbs). Dessa antikroppsvarianter har isolerats från patienter som tillfrisknat från infektion. Både DNA-sekvenser och strukturer av antikropparna finns offentligt tillgängliga. Dessa fyra antikroppar har också visats kunna binda till E2 som är ett membranbundet glykoprotein hos HCV som är centralt för viral adhesion och fusion. Interaktionen mellan dessa mAbs och E2 har visat sig neutralisera virulens, vilket gör dem till lovande kandidater för denna studie. Tre av fyra mAbs kunde klonas och produceras framgångsrikt. Försöket med HEPC74 misslyckades på grund av ett fel i plasmidsekvensen och just som western blot skulle genomföras för att bekräfta sekretion av en alternativ klon avslutades the praktiska arbetet med anledning av Covid-19 utbrottet. Resultaten visar entydigt att tre av fyra mAb producerades framgångsrikt. Det går dock att anta att det andra försöket med HEPC74 sannolikt också lyckades pga perfekt sekventiell matchning. Då det huvudsakliga syftet med projektet var att framgångsrikt klona och producera dessa fyra antikroppar så kan studien anses vara framgångsrik. Slutligen så undersöktes huruvida samma förfarande kunde appliceras mot SARS-CoV-2 genom kloning och produktion av anti-RBD IgG och tester av viral neutralisering.
APA, Harvard, Vancouver, ISO, and other styles
10

Andersson, Christin. "Production and delivery of recombinant subunit vaccines." Doctoral thesis, KTH, Biotechnology, 2000. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-3027.

Full text
Abstract:

Recombinant strategies are today dominating in thedevelopment of modern subunit vaccines. This thesis describesstrategies for the production and recovery of protein subunitimmunogens, and how genetic design of the expression vectorscan be used to adapt the immunogens for incorporation intoadjuvant systems. In addition, different strategies fordelivery of subunit vaccines by RNA or DNA immunization havebeen investigated.

Attempts to create general production strategies forrecombinant protein immunogens in such a way that these areadapted for association with an adjuvant formulation wereevaluated. Different hydrophobic amino acid sequences, beingeither theoretically designed or representing transmembraneregions of bacterial or viral origin, were fused on gene leveleither N-terminally or C-terminally to allow association withiscoms. In addition, affinity tags derived fromStaphylococcus aureusprotein A (SpA) or streptococcalprotein G (SpG), were incorporated to allow efficient recoveryby means of affinity chromatography. A malaria peptide, M5,derived from the central repeat region of thePlasmodium falciparumblood-stage antigen Pf155/RESA,served as model immunogen in these studies. Furthermore,strategies forin vivoorin vitrolipidation of recombinant immunogens for iscomincorporation were also investigated, with a model immunogendeltaSAG1 derived fromToxoplasma gondii. Both strategies were found to befunctional in that the produced and affinity purified fusionproteins indeed associated with iscoms. The iscoms werefurthermore capable of inducing antigen-specific antibodyresponses upon immunization of mice, and we thus believe thatthe presented strategies offer convenient methods for adjuvantassociation.

Recombinant production of a respiratory syncytial virus(RSV) candidate vaccine, BBG2Na, in baby hamster kidney(BHK-21) cells was investigated. Semliki Forest virus(SFV)-based expression vectors encoding both intracellular andsecreted forms of BBG2Na were constructed and found to befunctional. Efficient recovery of BBG2Na could be achieved bycombining serum-free production with a recovery strategy usinga product-specific affinity-column based on a combinatoriallyengineered SpA domain, with specific binding to the G proteinpart of the product.

Plasmid vectors encoding cytoplasmic or secreted variants ofBBG2Na, and employing the SFV replicase for self-amplification,was constructed and evaluated for DNA immunization against RSV.Both plasmid vectors were found to be functional in terms ofBBG2Na expression and localization. Upon intramuscularimmunization of mice, the plasmid vector encoding the secretedvariant of the antigen elicited significant anti-BBG2Na titersand demonstrated lung protective efficacy in mice. This studyclearly demonstrate that protective immune responses to RSV canbe elicited in mice by DNA immunization, and that differentialtargeting of the antigens expressed by nucleic acid vaccinationcould significantly influence the immunogenicity and protectiveefficacy.

We further evaluated DNA and RNA constructs based on the SFVreplicon in comparison with a conventional DNA plasmid forinduction of antibody responses against theP. falciparumPf332-derived antigen EB200. In general,the antibody responses induced were relatively low, the highestresponses surprisingly obtained with the conventional DNAplasmid. Also recombinant SFV suicide particles inducedEB200-reactive antibodies. Importantly, all immunogens inducedan immunological memory, which could be efficiently activatedby a booster injection with EB200 protein.

Keywords: Affibody, Affinity chromatography, Affinitypurification, DNA immunization, Expression plasmid, Fusionprotein, Hydrophobic tag, Iscoms, Lipid tagging, Malaria,Mammalian cell expression, Recombinant immunogen, RespiratorySyncytial Virus, Semliki Forest virus, Serum albumin,Staphylococcus aureusprotein A, Subunit vaccine,Toxoplasma gondii

APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Plasmid production"

1

Perinot, Glen. Genomic analysis of human papillomavirus types 16 and 18: Production of recombinant plasmid : part I in the production of a recombinant vaccine for human papillomavirus. Sudbury, Ont: Laurentian University, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

PPLA 2003, Messina and Catania, Italy, 18-19 September 2003. Plasma Production by Laser Ablation: PPLA 2003. Singapore: World Scientific Publishing, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bertolini, Joseph, Neil Goss, and J. M. Curling. Production of plasma proteins for therapeutic use. Hoboken, N.J: John Wiley & Sons, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bertolini, Joseph, Neil Goss, and John Curling, eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118356807.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cham, Yuen-wai. A study of digital printing in plastic card production. London: LCP, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Formulation, &. Production Conference (1996 Indianapolis Ind ). Powder coating: Formulation & Production Conference : Tuesday, September 17, 1996, Westin Hotel, Indianapolis, IN : conference proceedings. Alexandria, VA (2121 Eisenhower Ave., Suite 401, Alexandria 22314): The Institute, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bogenschütz, August Friedrich. Analysis and testing in production of circuit boards and plated plastics. Teddington, Middlesex, England: Finishing Publications, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jalufka, N. W. Laser production and heating of plasma for MHD application. [Washington, DC]: National Aeronautics and Space Administration, Scientific and Technical Information Division, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jalufka, N. W. Laser production and heating of plasma for MHD application. [Washington, DC]: National Aeronautics and Space Administration, Scientific and Technical Information Division, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schoukens, A. F. S. The production of refined ferromanganese in a transferred-arc plasma furnace. Randburg, South Africa: Council for Mineral Technology, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Plasmid production"

1

Shoda, Makoto. "Surfactin Production and Plasmid Stability." In Biocontrol of Plant Diseases by Bacillus subtilis, 263–84. Boca Raton, Florida : CRC Press, 2019. |: CRC Press, 2019. http://dx.doi.org/10.1201/9780429027635-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brand, Eva, Kathrin Ralla, and Peter Neubauer. "Strategies for Plasmid DNA Production inEscherichia coli." In Biopharmaceutical Production Technology, 1–41. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527653096.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lara, Alvaro R., and Octavio T. Ramírez. "Plasmid DNA Production for Therapeutic Applications." In Recombinant Gene Expression, 271–303. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-433-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lara, Alvaro R., and Octavio T. Ramírez. "Plasmid DNA Production for Therapeutic Applications." In Recombinant Gene Expression, E1. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-433-9_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schmeer, Marco, and Martin Schleef. "Production of Plasmid DNA as Pharmaceutical." In Methods in Molecular Biology, 315–26. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2727-2_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schleef, Martin, and Markus Blaesen. "Production of Plasmid DNA as Pharmaceutical." In Gene Therapy of Cancer, 471–95. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-561-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hanak, Julian A. J., and Rocky M. Cranenburgh. "Antibiotic-Free Plasmid Selection and Maintenance in Bacteria." In Recombinant Protein Production with Prokaryotic and Eukaryotic Cells. A Comparative View on Host Physiology, 111–24. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-015-9749-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kelly, Michael D., and Joel E. Mortensen. "A Low-Copy Number Plasmid Mediating β-Lactamase Production by Xanthomonas Maltophilia." In Antimicrobial Resistance, 71–80. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4757-9203-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mairhofer, Juergen, and Alvaro R. Lara. "Advances in Host and Vector Development for the Production of Plasmid DNA Vaccines." In Methods in Molecular Biology, 505–41. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0345-0_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hughes, Stephen R., Tauseef R. Butt, Scott Bartolett, and Steven B. Riedmuller. "Automated Systems of Plasmid-Based Functional Proteomics to Improve Microbes for Biofuel Production." In Microbiology Monographs, 259–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-21467-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Plasmid production"

1

Zhang, Xue-Qing, Mark Chen, Robert Lam, Xiaoyang Xu, Eiji Osawa, and Dean Ho. "A Platform Approach to Gene Delivery via Surface Modified Nanodiamonds." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13340.

Full text
Abstract:
The purpose of gene therapy is to introduce foreign genetic material into host cells to either supplement aberrant genes or to endow additional biological functions. To date, however, there has been only modest progress towards this goal, mainly due to the lack of safe, effective and broadly applicable delivery methods. Functional nanodiamonds (NDs) are rapidly emerging as promising platform carriers for next-generation therapeutics due to their innate biocompatibility, scalability, precise particle distribution, high surface area-to-volume ratio, near-spherical aspect ratio, and easily adaptable carbon surface for bioagent attachment. NDs have been functionalized with a range of therapeutics, proteins, antibodies, DNA, polymers, and other assorted biological agents. Furthermore, NDs are stable and dispersible in water, making them a promising and clinically important modality in improving the efficacy of the treatment of diseases and even some cancers at the molecular level. Mitochondrial function (MTT) and luminescent ATP production assays have demonstrated that NDs are not toxic to a wide variety of cell types. In this study, we functionalized NDs with amine groups via either covalent attachment of (3-aminopropyl) trimethoxysilane or surface immobilization of 800 Da low molecular weight polyethyleneimine (LMW PEI800) for plasmid DNA delivery. The latter delivery approach combines complementary characteristics of PEI800 and NDs to create a hybrid material that exhibits the high transfection efficiency of high molecular weight PEI, but without the inherent high cytotoxicity.
APA, Harvard, Vancouver, ISO, and other styles
2

Amoretti, M. "Non-Destructive Positron Plasma Diagnostics for Antihydrogen Production." In NON-NEUTRAL PLASMA PHYSICS V: Workshop on Non-Neutral Plasmas. AIP, 2003. http://dx.doi.org/10.1063/1.1635167.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Higaki, H., Y. Enomoto, N. Kuroda, K. Michishio, D. J. Murtagh, S. Ulmer, S. Van Gorp, et al. "Towards the production of anti-hydrogen beams." In NON-NEUTRAL PLASMA PHYSICS VIII: 10th International Workshop on Non-Neutral Plasmas. AIP, 2013. http://dx.doi.org/10.1063/1.4796069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baumer, Stefan M. B., Wim A. G. Timmers, Mark Krichever, and Vladimir Gurevich. "Temperature-compensated plastic lens for visible light." In Optical Systems Design and Production, edited by Fritz Merkle. SPIE, 1999. http://dx.doi.org/10.1117/12.360028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fukumasa, Osamu. "Isotope Effect of H−/D− Volume Production in Low-Pressure H2/D2 Plasmas — Negative Ion Densities versus Plasma Parameters." In PRODUCTION AND NEUTRALIZATION OF NEGATIVE IONS AND BEAMS: 10th International Symposium on Production and Neutralization of Negative Ions and Beams. AIP, 2005. http://dx.doi.org/10.1063/1.1908283.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

PANDEY, UMESH, JAN ARILD STORMYR, ALIREZA HASSANI, RAJAN JAISWAL, HILDEGUNN H. HAUGEN, and BRITT M. E. MOLDESTAD. "PYROLYSIS OF PLASTIC WASTE TO ENVIRONMENTALLY FRIENDLY PRODUCTS." In ENERGY PRODUCTION AND MANAGEMENT 2020. Southampton UK: WIT Press, 2020. http://dx.doi.org/10.2495/epm200071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vallinga, P. M., D. C. Schram, and H. J. Hopman. "Plasma neutralizers." In Production and neutralization of negative ions and beams. AIP, 1990. http://dx.doi.org/10.1063/1.39644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kuroda, N., Y. Nagata, H. A. Torii, D. Barna, J. Eades, D. Horváth, M. Hori, et al. "Radial compression of antiproton cloud for production of ultraslow antiproton beams." In NON-NEUTRAL PLASMA PHYSICS VII: Workshop on Non-Neutral Plasmas 2008. AIP, 2009. http://dx.doi.org/10.1063/1.3122278.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fauchais, P., J. F. Coudert, and B. Pateyron. "Production of Thermal plasmas." In Proceedings of the International School of Plasma Physics “Piero Caldirola”. WORLD SCIENTIFIC, 1996. http://dx.doi.org/10.1142/9789814447171_0001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

El-Fayoumi, Amr Mohamed, Karim S. Zaki, and Ahmed S. Abou-Sayed. "3D Hydraulic Fracture Simulation for Injection in Plastic Shales." In SPE Production and Operations Symposium. Society of Petroleum Engineers, 2011. http://dx.doi.org/10.2118/142263-ms.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Plasmid production"

1

O'Connell, Caolionn L., and Phys Dept /Stanford U. Plasma Production via Field Ionization. US: Stanford Linear Accelerator Center (SLAC), September 2005. http://dx.doi.org/10.2172/878428.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tsidulko, Yu A., and H. L. Berk. Plasma analog of particle-pair production. Office of Scientific and Technical Information (OSTI), September 1996. http://dx.doi.org/10.2172/392841.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Coensgen, F. H., A. H. Futch, and A. W. Molvik. Linear plasma-based tritium production facility. Office of Scientific and Technical Information (OSTI), February 1989. http://dx.doi.org/10.2172/6338201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nair, Ajay, and Brandon H. Carpenter. Sustainable Plastic Mulch Options for Vegetable Production Systems. Ames: Iowa State University, Digital Repository, 2014. http://dx.doi.org/10.31274/farmprogressreports-180814-451.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nair, Ajay, and Bernard J. Havlovic. Colored Plastic Mulches for High Tunnel Tomato Production. Ames: Iowa State University, Digital Repository, 2014. http://dx.doi.org/10.31274/farmprogressreports-180814-670.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sears, J. W. Plasma quench production of titanium from titanium tetrachloride. Office of Scientific and Technical Information (OSTI), October 1994. http://dx.doi.org/10.2172/116695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Trow, J. R. H/sup -/ production in a multicusp microwave plasma. Office of Scientific and Technical Information (OSTI), March 1985. http://dx.doi.org/10.2172/5638985.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Author, Not Given. Plasma Carbothermic Reduction for Boron-Based Chemical Hydride Production. Office of Scientific and Technical Information (OSTI), January 2011. http://dx.doi.org/10.2172/1003730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

R. A. Cordes and A. Donaldson. Titanium Metal Powder Production by the Plasma Quench Process. Office of Scientific and Technical Information (OSTI), September 2000. http://dx.doi.org/10.2172/765301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Author, Not Given. Modular Hybrid Plasma Systems for Low Cost Production of Nanoparticles. Office of Scientific and Technical Information (OSTI), February 2009. http://dx.doi.org/10.2172/964934.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Plasmid production' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography